Clinical Trial Update: PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a PD-L1 inhibitor with radiotherapy, with or without ursodeoxycholic acid, in recurrent/metastatic HER2-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)
• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING